Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of CEBPβ depletion on enhancer responses to dexamethasone in Multiple Myeloma cells

ABSTRACT: Multiple myeloma (MM) is the second most common hematological cancer. While MM is considered treatable, it remains incurable due to the eventual drug resistance in nearly all patients. A cornerstone therapeutic for MM is dexamethasone, a synthetic glucocorticoid with anti-inflammatory and anti-myeloma properties. In this study, we investigate the role of CEBPβ in modulating enhancer activities, measured by H3K27ac, in response to dexamethasone in MM cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE312300 | GEO | 2025/12/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Impact of CEBPβ depletion on enhancer responses to dexamethasone in Multiple Myeloma cells

Project description:Impact of CEBPβ depletion on enhancer responses to dexamethasone in Multiple Myeloma cells

| PRJNA1372804 | ENA

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy

Project description:One of the cornerstone drugs in the treatment of multiple myeloma (MM) are glucocorticoids. Because MM cells hijack the bone marrow microenvironment to obtain growth and survival signals, resistance to glucocorticoid-induced apoptosis emerges, yet, the underlying mechanisms remain poorly characterized. Here we identify that the chemokine receptor CCR1 together with its main ligand CCL3, plays a pivotal role in reducing glucocorticoid sensitivity of MM cells. We show that blocking of CCR1 signalling with the antagonist BX471 enhances the anti-MM effects of the glucorticoid dexamethasone in several MM cell lines, primary patient material and in a myeloma xenograft mouse model. Mechanistically, the drug combination shifts the balance between pro- and antiapoptotic proteins towards apoptosis and deregulates lysosomal proteins. We further find that the glucocorticoid-induced downregulation of CCR1 mRNA and protein is blunted in a glucocorticoid-resistance onset model. Finally, we demonstrate that CCR1 inhibition partially reverses GC-resistance, hereby offering a viable glucocorticoid resensitization strategy for MM treatment.

2025-06-18 | PXD055337 | Pride

Machine learning-assisted classification of responders and non-responders to bortezomib treatment regimens PAD and VCD using new experimental dataset of 58 multiple myeloma RNA sequencing profiles

Project description:Multiple myeloma (MM) is a hematological cancer which arises from abnormal antibody producing white blood plasma cells. MM affected approximately 500 000 people and results in ~100 000 deaths annually, being currently considered treatable but uncurable. There are several MM chemotherapy treatment regimens, among which ten include bortezomib, a proteasome-targeted drug. Patients with MM respond differently on bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated molecular profiles of MM that could be used to establish novel molecular diagnostics. In this study we report new molecular profiles for 58 MM patients annotated with data on two chemotherapy regimens which include bortezomib, doxorubicin, and dexamethasone (PAD) or bortezomib, cyclophosphamide, and dexamethasone (VCD). MM biosamples were taken prior to first line chemotherapy treatments and subjected to RNA sequencing.

2021-10-01 | GSE159426 | GEO

Inhibition of protein translation is a major mechanism for the activity of the pan-PIM kinase inhibitor PIM447 in combination with Pomalidomide-dexamethasone in multiple myeloma

Project description:The overexpression of PIM kinases in hematologic malignancies, including multiple myeloma, make PIM inhibitors an attractive therapeutic strategy for these diseases. Recent preclinical data from our group demonstrated the anti-myeloma effect of the pan-PIM kinase inhibitor PIM447, along with its synergistic effect with standard of care anti-myeloma agents. Based on those previous data, we have evaluated here the in vitro and in vivo activity of the triple combination of PIM447 + pomalidomide + dexamethasone (PIM-Pd). Our results show that this combination exerts a potent anti-myeloma effect in vitro, even in presence of microenvironment cells, and, in vivo, it markedly delays tumor growth and prolongs survival. Mechanism of action studies suggest that the combination PIM-Pd inhibits protein translation processes through the convergent inhibition of mTORC1, which disrupts the function eIF4E, and c-Myc. As a consequence, cell cycle arrest and disruption of metabolic pathways, including glycolysis and lipid biosynthesis, is induced, inhibiting myeloma cell proliferation. Altogether, these data support the potential future clinical development of the triple combination PIM-Pd for the treatment of patients with MM.

2020-11-02 | GSE138440 | GEO

Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure

Project description:In vivo changes of gene expression profiles (GEP) of tumor cells 48hr after single agent therapy may vary by treatment and provide added predictive power over baseline GEP information. In newly diagnosed patients with multiple myeloma (MM), GEP data were obtained on tumor cells prior to and 48hr after dexamethasone (n=45) or thalidomide treatment (n=42); in case of relapsed MM, GEP data were obtained prior to (n=36) and after (n=19) lenalidomide administration. Dexamethasone and thalidomide induced both common and unique GEP changes. Combined baseline and 48hr changes of GEP in a subset of genes that were discovered in newly diagnosed MM also predicted event-free and overall survival in relapsed patients receiving lenalidomide. Combined with baseline molecular features, changes in GEP following short-term single agent treatment may help guide treatment decisions for patients with MM. The genes whose altered expression is related to eventual survival may also point to mechanisms of action and resistance to different classes of drugs. Keywords: drug response

2008-08-04 | GSE8546 | GEO

Transcription profiling of human myeloma cells following short term in-vivo drug exposure

2008-10-18 | E-GEOD-8546 | biostudies-arrayexpress

Inhibition of the kinesin spindle protein enhances the activity of pomalidomide and dexamethasone in multiple myeloma [In Vivo]

Project description:Kinesin spindle protein (KSP) inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (Arry-520), a KSP inhibitor, has demonstrated activity in heavily pretreated multiple myeloma (MM) patients. The aim of this work was to investigate the activity of filanesib in combination with an IMiDs plus dexamethasone backbone, and the mechanisms underlying the potential synergistic effect. Results: Filanesib showed in vitro and in vivo synergy with all IMiDs plus dexamethasone treatment, particularly with the pomalidomide combination (PDF). Importantly, the in vivo synergy observed in this combination was more evident in large, highly proliferative tumors, and it was shown to be mediated by impairment of mitosis transcriptional control, an increase in monopolar spindles, cell cycle arrest and the induction of apoptosis in cells in proliferative phases. In addition, PDF increased the activation of the proapoptotic protein Bax, which has been previously associated with sensitivity to filanesib, and could potentially be used as a predictive biomarker of response to this combination. Conclusions: Our results provide preclinical evidence for the potential benefit of the combination of filanesib with pomalidomide and dexamethasone and es-tablished the basis for a recently activated trial being conducted by the Spanish MM group investigating this combination in relapsed MM patients.

2018-02-14 | GSE94336 | GEO

Inhibition of the kinesin spindle protein enhances the activity of pomalidomide and dexamethasone in multiple myeloma [In Vitro]

2018-02-14 | GSE94334 | GEO

The BET bromodomain inhibitor CPI203 improves lenalidomide activity in in vitro and in vivo models of multiple myeloma by synergistic blockade of Ikaros and c-Myc signaling

Project description:Multiple myeloma (MM) cells were treated with the BET inhibitor CPI203 alone and in combination with lenalidomide plus dexamethasone in vitro and in vivo (mouse xenograft). We used microarrays to uncover the mechanisms underlying CPI-203 activity in MM, alone and in combination with lenalidomide plus dexamethasone (combo).

2016-09-28 | GSE87403 | GEO

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

| PRJNA687056 | ENA